Company Encyclopedia
View More
name
Heamonetics
HAE.US
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient’s overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions.
330.79 B
HAE.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care SuppliesIndustry
Industry Ranking14/42
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE19.47%A
    • Profit Margin12.67%B
    • Gross Margin59.45%A
  • Growth ScoreC
    • Revenue YoY-2.45%D
    • Net Profit YoY35.84%B
    • Total Assets YoY-3.29%D
    • Net Assets YoY-3.38%D
  • Cash ScoreC
    • Cash Flow Margin789.49%B
    • OCF YoY-2.45%D
  • Operating ScoreC
    • Turnover0.53C
  • Debt ScoreD
    • Gearing Ratio65.23%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Director Mark W. Kroll Reports Acquisition of Haemonetics Corporation Common Shares

    Mark W. Kroll, Director of Haemonetics Corporation, has reported the acquisition of common shares of the company. The full filing is available through the provided link. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial or legal advice. Haemonetics Corporation published the original content via EDGAR on November 12, 2025.

    Reuters·
    US
    HAE
    +2.32%
    Reuters·
    US
    HAE
    +2.32%

    Haemonetics (NYSE:HAE) Posts Quarterly Earnings Results, Beats Estimates By $0.15 EPS

    Haemonetics (NYSE:HAE) reported quarterly earnings of $1.27 EPS, surpassing estimates of $1.12 by $0.15. The company had revenue of $327.32 million, exceeding the expected $311.61 million, although revenue declined by 5.3% year-over-year. Haemonetics updated its FY 2026 guidance to 4.800-5.00 EPS. The stock traded up to $68.70, with a market cap of $3.31 billion. Analysts have mixed ratings, with a consensus rating of "Moderate Buy" and a target price of $78.50. Institutional investors hold 99.67% of the company's stock.

    Market Beat·
    US
    HAE
    +2.32%
    Market Beat·
    US
    HAE
    +2.32%

    Haemonetics Reports Positive Earnings Call with Growth Highlights

    Haemonetics Corporation reported positive results in its Q2 earnings call, highlighting a 9% increase in organic revenue and a 13% rise in adjusted EPS to $1.27. The company achieved record gross margin expansion at 60.5% and strong operating cash flow of $111 million, up 128% year-over-year. Despite a 5% decline in overall revenue due to portfolio transitions, Haemonetics raised its free cash flow guidance to $170-$210 million and remains optimistic about future growth, expecting organic growth of 7%-10% and adjusted EPS of $4.80-$5.00 for the full year.

    Tip Ranks·
    US
    HAE
    +2.32%
    Tip Ranks·
    US
    HAE
    +2.32%

    Sector Update: Health Care Stocks Ease Late Afternoon

    Health care stocks declined late Friday, with the NYSE Health Care Index down 0.1%. Gilead Sciences shares fell 4.7% after a trial for Trodelvy failed to meet its primary endpoint. Moderna aims for cash breakeven by 2028, with a price target adjustment to $30. Globus Medical was upgraded to buy, with shares surging 36%. Haemonetics was upgraded to neutral, with shares rising 2.2%.

    fidelity·
    US
    HAE
    +2.32%
    US
    MRNA
    +1.23%
    US
    GILD
    -1.90%
    fidelity·
    US
    HAE
    +2.32%
    US
    MRNA
    +1.23%
    US
    GILD
    -1.90%

    BTIG Research Forecasts Strong Price Appreciation for Haemonetics (NYSE:HAE) Stock

    BTIG Research has raised its price target for Haemonetics (NYSE:HAE) from $85.00 to $88.00, maintaining a "buy" rating. This suggests a potential upside of 33.83% from the current price. Other analysts have varied opinions, with Citigroup lowering its target to $64.00 and Weiss Ratings downgrading to a "sell". Haemonetics' stock rose 29.6% recently, trading at $65.76, with a market cap of $3.17 billion. The company reported $1.27 EPS for the last quarter, exceeding estimates, and anticipates 4.55 EPS for the current year.

    Market Beat·
    US
    HAE
    +2.32%
    Market Beat·
    US
    HAE
    +2.32%
    © 2025 Longbridge｜Disclaimer